Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Published Online
on October 9, 2006

Circulation. 2006
Published online before print October 9, 2006, doi: 10.1161/CIRCULATIONAHA.105.593483
A more recent version of this article appeared on October 24, 2006
This Article
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
Circulation: October 24, 2006, Volume 114, Number 17
Right arrow All Versions of this Article:
114/17/1847    most recent
CIRCULATIONAHA.105.593483v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Eldrup, N.
Right arrow Articles by Nordestgaard, B. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Eldrup, N.
Right arrow Articles by Nordestgaard, B. G.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
Medline Plus Health Information
*Stroke
Related Collections
Right arrow Pathophysiology
Right arrow Risk Factors
Right arrow Carotid Stenosis
Right arrowRelated Article

Submitted on October 7, 2005
Revised on August 4, 2006
Accepted on August 29, 2006

Elevated Matrix Metalloproteinase-9 Associated With Stroke or Cardiovascular Death in Patients With Carotid Stenosis

Nikolaj Eldrup MD, Marie-Louise Moes Grønholdt MD, PhD, DMSc, Henrik Sillesen MD, DMSc, and Børge G. Nordestgaard MD, DMSc*

From the Department of Vascular Surgery, Rigshospitalet, Copenhagen University Hospital (N.E., M.-L.M.G., H.S.) and Department of Clinical Biochemistry, Herlev University Hospital, University of Copenhagen (N.E., B.G.N.), Copenhagen, Denmark.

* To whom correspondence should be addressed. E-mail: brno{at}herlevhosp.kbhamt.dk.

Background--Matrix metalloproteinase-9 could exhibit an important role in the destabilization of atherosclerotic carotid plaques. We hypothesized that in patients with carotid stenosis, elevated levels of plasma matrix metalloproteinase-9 are associated with ipsilateral stroke or cardiovascular death.

Methods and Results--We followed up 207 patients with ≥50% carotid stenosis initially for a mean of 4.4 years, during which time 53 patients developed ipsilateral stroke or died of cardiovascular causes. The cumulative incidence of ipsilateral stroke or cardiovascular death was higher in those with matrix metalloproteinase-9 above versus below the median of 41.9 ng/mL (log-rank P=0.002). Matrix metalloproteinase-9 above versus below the median had a hazard ratio for ipsilateral stroke or cardiovascular death of 1.9 (95% confidence interval [CI], 1.1 to 3.5); during extended follow-up, this remained significant until 10 years. The absolute risk of ipsilateral stroke or cardiovascular death at 4.4 years was 34% and 17% in those with matrix metalloproteinase-9 above and below the median, respectively. Elevated matrix metalloproteinase-9 and an echolucent plaque on B-mode ultrasound versus a low matrix metalloproteinase-9 and an echorich plaque had a hazard ratio for ipsilateral stroke or cardiovascular death of 4.4 (95% CI, 1.8 to 11.1) and for ipsilateral stroke of 3.3 (95% CI, 1.1 to 9.7).

Conclusions--Elevated levels of matrix metalloproteinase-9 in patients with ≥50% carotid stenosis were associated with a 2-fold risk of ipsilateral stroke or cardiovascular death. Combining elevated matrix metalloproteinase-9 and plaque echolucency was associated with a 4-fold risk for ipsilateral stroke or cardiovascular death and a 3-fold risk for ipsilateral stroke.


Key words: atherosclerosis • carotid artery diseases • matrix metalloproteinases


Related Article:

Issue Highlights
Circulation 2006 114: 1793. [Extract] [Full Text]



This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
S. Fujimoto, D. Hartung, S. Ohshima, D. S. Edwards, J. Zhou, P. Yalamanchili, M. Azure, A. Fujimoto, S. Isobe, Y. Matsumoto, et al.
Molecular Imaging of Matrix Metalloproteinase in Atherosclerotic Lesions: Resolution With Dietary Modification and Statin Therapy
J. Am. Coll. Cardiol., December 2, 2008; 52(23): 1847 - 1857.
[Abstract] [Full Text] [PDF]


Home page
QJMHome page
P. Welsh, P.H. Whincup, O. Papacosta, S.G. Wannamethee, L. Lennon, A. Thomson, A. Rumley, and G.D.O. Lowe
Serum matrix metalloproteinase-9 and coronary heart disease: a prospective study in middle-aged men
QJM, October 1, 2008; 101(10): 785 - 791.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
R. R. S. Packard and P. Libby
Inflammation in Atherosclerosis: From Vascular Biology to Biomarker Discovery and Risk Prediction
Clin. Chem., January 1, 2008; 54(1): 24 - 38.
[Abstract] [Full Text] [PDF]